Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The surface‐exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor

View through CrossRef
AbstractTriggering receptor expressed in myeloid (TREM) cells 2, a receptor expressed by myeloid cells, osteoclasts and microglia, is known to play a protective role in bones and brain. Mutations of the receptor (or of its coupling protein, DAP12) sustain in fact a genetic disease affecting the two organs, the polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy (PLOSL or Nasu‐Hakola disease). So far, specific agonist(s) of TREM2 have not been identified and its (their) transduction mechanisms are largely unknown. Heat shock protein 60 (Hsp60) is a mitochondrial chaperone that can also be harboured at the cell surface. By using constructs including the extracellular domain of TREM2 and the Fc domain of IgGs we have identified Hsp60 as the only TREM2‐binding protein exposed at the surface of neuroblastoma N2A cells and astrocytes, and lacking in U373 astrocytoma. Treatment with Hsp60 was found to stimulate the best known TREM2‐dependent process, phagocytosis, however, only in the microglial N9 cells rich in the receptor. Upon TREM2 down‐regulation, the Hsp60‐induced stimulation of N9 phagocytosis was greatly attenuated. Hsp60 is also released by many cell types, segregated within exosomes or shedding vesicles which might then undergo dissolution. However, the affinity of its binding (Kd = 3.8 μM) might be too low for the soluble chaperone released from the vesicles to the extracellular space to induce a significant activation of TREM2. It might in contrast be appropriate for the binding of TREM2 to Hsp60 exposed at the surface of cells closely interacting with microglia. The ensuing stimulation of phagocytosis could play protective effects on the brain.
Title: The surface‐exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor
Description:
AbstractTriggering receptor expressed in myeloid (TREM) cells 2, a receptor expressed by myeloid cells, osteoclasts and microglia, is known to play a protective role in bones and brain.
Mutations of the receptor (or of its coupling protein, DAP12) sustain in fact a genetic disease affecting the two organs, the polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy (PLOSL or Nasu‐Hakola disease).
So far, specific agonist(s) of TREM2 have not been identified and its (their) transduction mechanisms are largely unknown.
Heat shock protein 60 (Hsp60) is a mitochondrial chaperone that can also be harboured at the cell surface.
By using constructs including the extracellular domain of TREM2 and the Fc domain of IgGs we have identified Hsp60 as the only TREM2‐binding protein exposed at the surface of neuroblastoma N2A cells and astrocytes, and lacking in U373 astrocytoma.
Treatment with Hsp60 was found to stimulate the best known TREM2‐dependent process, phagocytosis, however, only in the microglial N9 cells rich in the receptor.
Upon TREM2 down‐regulation, the Hsp60‐induced stimulation of N9 phagocytosis was greatly attenuated.
Hsp60 is also released by many cell types, segregated within exosomes or shedding vesicles which might then undergo dissolution.
However, the affinity of its binding (Kd = 3.
8 μM) might be too low for the soluble chaperone released from the vesicles to the extracellular space to induce a significant activation of TREM2.
It might in contrast be appropriate for the binding of TREM2 to Hsp60 exposed at the surface of cells closely interacting with microglia.
The ensuing stimulation of phagocytosis could play protective effects on the brain.

Related Results

TREM2 knockout, but not the R47H Alzheimer’s variant, reduces neural phagocytosis and survival of human iPSC-derived macrophages
TREM2 knockout, but not the R47H Alzheimer’s variant, reduces neural phagocytosis and survival of human iPSC-derived macrophages
Abstract BACKGROUND: TREM2 is a microglial cell surface receptor, with risk mutations linked to Alzheimer’s disease (AD), including R47H. Binding of ligands to TREM2 trigge...
Characterization of the first TREM2 small molecule agonist, VG‐3927, for clinical development in Alzheimer’s disease
Characterization of the first TREM2 small molecule agonist, VG‐3927, for clinical development in Alzheimer’s disease
AbstractBackgroundTREM2 is a lipid‐sensing receptor expressed by microglial sub‐populations within neuropathological microenvironments, whose downstream signaling promotes microgli...
Meprin β cleaves TREM2 and controls its phagocytic activity on macrophages
Meprin β cleaves TREM2 and controls its phagocytic activity on macrophages
Abstract The triggering receptor expressed on myeloid cells 2 (TREM2) is a multifunctional surface protein that affects survival, migration, ...
Use of CRISPR/Cas9 Gene Editing Methods to Investigate the Mechanism of Trem2-Dependent Gene Expression in Macrophages
Use of CRISPR/Cas9 Gene Editing Methods to Investigate the Mechanism of Trem2-Dependent Gene Expression in Macrophages
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a surface receptor expressed in macrophages during tissue injury. This receptor plays a role in driving phagocytosis and...
Targeting Trem2 Signaling as a Potential Therapeutic Strategy for HFpEF
Targeting Trem2 Signaling as a Potential Therapeutic Strategy for HFpEF
Trem2 is a transmembrane receptor predominantly expressed in myeloid cells, specifically in monocytes, macrophages, and microglia. In recent years, the Trem2 receptor has been reco...

Back to Top